189 studies found for:    Open Studies | "Blood Platelet Disorders"
Show Display Options
Rank Status Study
21 Recruiting The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia
Conditions: Polycythemia Vera (PV);   Essential Thrombocythemia (ET)
Interventions: Drug: Ruxolitinib;   Drug: BAT
22 Not yet recruiting Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS
Condition: Atypical Hemolytic Uremic Syndrome
Intervention: Drug: eculizumab
23 Recruiting Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia
Condition: Immune Thrombocytopenia
Intervention: Drug: PRTX-100
24 Recruiting Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Conditions: Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Small Lymphocytic Lymphoma;   Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Chronic Myeloid Leukemia;   Chronic Myeloproliferative Disorders;   Multiple Myeloma;   Plasma Cell Neoplasm;   Plasma Cell Dyscrasia;   Myelofibrosis;   Polycythemia Vera;   Essential Thrombocythemia;   Plasma Cell Leukemia
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total body irradiation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
25 Recruiting Caffeic Acid Combining High-dose Dexamethasone in Management of ITP
Condition: Immune Thrombocytopenia
Interventions: Drug: Caffeic acid tablets;   Drug: Dexamethasone;   Drug: placebo
26 Recruiting A Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura
Condition: Acquired Thrombotic Thrombocytopenic Purpura
Interventions: Biological: caplacizumab;   Biological: placebo
27 Recruiting Study of Voncento® in Subjects With Von Willebrand Disease
Condition: Von Willebrand Disease
Intervention: Biological: Voncento
28 Recruiting Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2
Condition: Heparin-induced Thrombocytopenia
Intervention: Procedure: Blood Draw
29 Recruiting Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Conditions: Primary Myelofibrosis (PMF);   Post-polycythemia Vera (Post-PV) Myelofibrosis;   Postessential Thrombocythemia (Post-ET) Myelofibrosis
Intervention: Drug: MMB
30 Not yet recruiting Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin
Conditions: Aneurysmal Subarachnoid Hemorrhage;   Neurobehavioral Manifestations;   Vasospasm, Intracranial;   Intracranial Aneurysm;   Heparin-induced Thrombocytopenia Type II
Intervention: Drug: Continuous Low-Dose Intravenous Unfractionated Heparin Infusion (14 days)
31 Not yet recruiting Prospective Study of Patients With Thrombocytopenia Following HSCT
Conditions: Thrombocytopenia;   Hematologic Diseases
Interventions: Drug: decitabine;   Drug: rhTPO
32 Recruiting Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease
Condition: Von Willebrand Disease
Intervention: Drug: plasma-derived FVIII/VWF concentrate Fanhdi
33 Not yet recruiting Investigating a Von Willebrand Factor (VWF) Functional Screening Assay for Assigning the Phenotypic Variants of Von Willebrand Disease (VWD)
Condition: Von Willebrands Disease
Intervention:
34 Recruiting Complement Inhibition in aHUS Dialysis Patients
Condition: Atypical Hemolytic Uremic Syndrome
Intervention: Drug: CCX168
35 Recruiting Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE
Condition: Thrombocytopenia
Interventions: Drug: Hydroxychloroquine;   Drug: Cyclophosphamide;   Drug: Azathioprine;   Drug: Methylprednisolone
36 Recruiting Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease
Condition: Myelofibrosis
Interventions: Drug: Idelalisib;   Drug: Ruxolitinib
37 Recruiting Study of Nivolumab in Patients With Myelofibrosis
Condition: Myeloproliferative Diseases
Interventions: Drug: Nivolumab;   Behavioral: Questionnaire;   Behavioral: Phone Call
38 Recruiting Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Interventions: Drug: RG7388;   Drug: Pegasys
39 Recruiting A Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients
Condition: Purpura, Thrombocytopenic, Idiopathic
Intervention: Drug: Hetrombopag Olamine
40 Not yet recruiting Eltrombopag in Second Line Adult Primary Immune Thrombosytopenia
Condition: Primacy Immune Thrombocytopenia
Intervention: Drug: Eltrombopag

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years